Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial

NCT04339712 is registered in ClinicalTrials.gov with Hellenic Institute for the Study of Sepsis as lead sponsor.

NCT NCT04339712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04339712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial
Lead sponsor
Hellenic Institute for the Study of Sepsis
Phase
Phase 2
Overall status
Completed
Start date
April 2, 2020
Completion date
January 8, 2021
Enrollment
102 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

corona virus infection, covid-19, macrophage activation syndrome, virus diseases